Open-Label, Multi-Center, Dose Escalation Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects With Previously Treated Multiple Myeloma.
Phase of Trial: Phase I/II
Latest Information Update: 10 Oct 2012
At a glance
- Drugs BIW 8962 (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 09 Apr 2012 Actual patient number (23) added as reported by ClinicalTrials.gov.
- 23 Sep 2011 Planned End Date changed from 1 Apr 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.
- 03 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.